Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.47 |
| ▸ | DRD3 | P35462 | 11/20 | 0.47 |
| ▸ | DRD4 | P21917 | 6/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20910187 | 0.86 | DRD2 (0.59) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL14922881 | 0.83 | DRD2 (0.68) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL26297471 | 0.81 | DRD2 (0.62) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL16258711 | 0.79 | DRD2 (0.40) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL26297474 | 0.78 | DRD2 (0.46) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL12410851 | 0.75 | CYP1A2 (0.49) | DRD2DRD3DRD4DRD1SRD5A1 | |
| SCHEMBL15450809 | 0.75 | DRD2 (0.44) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL15759222 | 0.74 | SRD5A1 (0.40) | DRD2DRD3DRD4DRD1MAPT | |
| SCHEMBL13961201 | 0.74 | SRD5A1 (0.40) | DRD2DRD1MAPTSRD5A1 | |
| SCHEMBL20910190 | 0.74 | DRD2 (0.47) | DRD2DRD3DRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CURZA GLOBAL, LLC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CLPP, RPN2, MPO | DRD2 2265/4885DRD3 1602/4885DRD4 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.